Shares of Amgen (AMGN) Sees Large Inflow of Net Money Flow

Amgen (AMGN): $53.96 million was the positive money flow into the stock on Tuesday and the up/down ratio of ticks was also in favor of the bulls at 1.67. The value of trades done on upticks was $134.69 million, whereas, trades done on downticks were valued at $80.73 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $50.33 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $50.33 million. Amgen (AMGN) fell $0.92 traded at $160.18, a change of -0.57% over the previous day. The stock is 3.82% for the week.


The company Insiders own 0.2% of Amgen shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -25.24% . Institutional Investors own 83.22% of Amgen shares. During last six month period, the net percent change held by insiders has seen a change of -25.24%. In an insider trading activity, The officer (EVP, Operations), of Amgen Inc, Balachandran Madhavan had unloaded 30,000 shares at $154.12 per share in a transaction on May 4, 2016. The total value of transaction was $4,623,600. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Shares of Amgen Inc. rose by 4.98% in the last five trading days and 4.64% for the last 4 weeks. Amgen Inc. is up 2.79% in the last 3-month period. Year-to-Date the stock performance stands at 1.13%.

Amgen (NASDAQ:AMGN): stock turned positive on Tuesday. Though the stock opened at $160.62, the bulls momentum made the stock top out at $162.28 level for the day. The stock recorded a low of $160.51 and closed the trading day at $161.96, in the green by 1.11%. The total traded volume for the day was 2,407,151. The stock had closed at $160.18 in the previous days trading.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.